Cornea

The study’s main outcome measures were the changes in those 2 parameters following treatment with teprotumumab.

The rationale for the study was anecdotal reports of the effects of breast milk used by mothers to treat blocked tear ducts, rashes, and a chemical corneal burn in babies.

The meetings support the company’s submission for its bioengineered corneal implants to eliminate corneal blindness.

The additions to the ANTERION Cornea App will be commercially available in February 2025

Lana Rifkin, MD, a uveitis specialist at Ophthalmic Consultants of Boston, shared insights into her work and her role as committee chair of the uveitis section for the upcoming EnVision Summit, which will be held from February 14 to 17, 2025, at the Caribe Hilton San Juan in Puerto Rico.

This year was brimming with advancements in eye care.

According to Robert Latkany, MD, understanding the causes and recognizing these diagnostic features are essential for effective treatment.

Trending topics and milestone stories from our year in ophthalmology.

Epioxa is a next-generation corneal cross-linking iLink therapy for the treatment of keratoconus.

In an interview with Ophthalmology Times, clinical trial investigator Zaina Al-Mohtaseb MD, noted the CLARA Phase 1/2 trial demonstrated the safety, efficacy, and simplicity of corneal endothelial cell injection therapy with a rho kinase inhibitor, offering a less invasive alternative to traditional corneal transplantation for treating corneal edema.

Research data published earlier this year could help clinicians gain a better understanding of what to look for in a specular microscope, and how to interpret inter- and intradevice repeatability results in a way that benefits their existing practice framework.

VisiRose, a company formed in collaboration with Provectus Biopharmaceuticals and the University of Miami Miller School of Medicine’s Bascom Palmer Eye Institute, is advancing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a non-invasive treatment for infectious keratitis, leveraging light-based technology and addressing antimicrobial resistance to improve outcomes for patients with severe eye infections globally.

BostonSight’s pilot study, published in Clinical Ophthalmology, explores the use of PROSE scleral lenses as a drug delivery system for cyclosporine 0.05% in treating dry eye disease, showing promising symptom relief and tolerability.

The incidence was comparable to that of daily wear soft contact lenses.

A Q&A with PPP Committee Cornea/External Disease Panel member Daniel S. Choi, MD.

A discussion with Shigeru Kinoshita, MD, PhD; and Edward J. Holland, MD.

Emmecell announced positive Phase 1 extension study results for EO2002, a nonsurgical cell therapy for corneal edema. The therapy improved vision, reduced central corneal thickness, and demonstrated strong safety, offering an alternative to corneal transplants.

Corneal confocal microscopy, semaglutide therapy offer treatment options

A study led by researchers at the University of Birmingham finds AI-powered models can match ophthalmologists in diagnosing infectious keratitis, offering promise for global eye care improvements.

John D. Sheppard, MD, MMSc, FACS, spoke with the Eye Care Network to provide some insight on post hoc analysis of the ESSENCE 1 trial dor dry eye disease.

According to OKYO Pharma, OK-101 is the first drug candidate to enroll patients specifically diagnosed with neuropathic corneal pain in a clinical trial. The Phase 2 trial is designed as a randomized, placebo-controlled, double-masked study to treat 48 NCP patients.

According to the company, in a confirmatory trial, Epioxa met pre-specified primary efficacy endpoint and exhibited positive tolerability and safety profiles through 12 months, supporting an anticipated NDA submission by the end of 2024.

A Norwegian study demonstrates that transplant rates continue to drop over time

The trial is assessing the safety and efficacy of EO2002 for the treatment of corneal edema.

In a study, a team of Chinese researchers looked at the mechanisms behind the development of EI and explored effective treatment options.

Vyznova is for the treatment of bullous keratopathy of the cornea, a sight-threatening and debilitating condition affecting the endothelial cells of the cornea.

TEPEZZA is the first and only medicine approved in Japan to treat active TED.

The new standard: Stabilizing keratoconus and improving vision.

Prevent Blindness is offering free resources to help educate the public and allied healthcare professionals on the many types of inflammatory eye diseases, and steps that should be taken to prevent vision loss.

Laura M. Periman, MD, shares her passion for dry eye disease, discussing her discovery of the Alpenglow Sign in Demodex blepharitis and her insights on research and education for clinicians. Periman will join the EyeCon 2024 faculty as Honorary Chair.